NMRA earnings analysis
What we found in NMRA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Neumora's second-quarter results show improving losses, with diluted EPS of $(0.23) and quarterly net loss of $43.1 million versus $(0.33) and $52.7 million, respectively, in the prior-year quarter. Liquidity remains the principal financial support, with $116.8 million of cash, cash equivalents and marketable securities expected to fund operations into Q3 2027, supplemented by $20.4 million of ATM proceeds in the first half. However, discontinuation of navacaprant in MDD after failed Phase 3 studies, a 35% workforce reduction, continuing accumulated losses of $1,280.7 million and potential financing dilution offset the earnings improvement.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- EPS loss narrowed sequentially and year over year
- Diluted EPS was $(0.23) for the quarter, compared with $(0.30) in 2026 Q1 and $(0.33) in 2025 Q2, indicating sequential and year-over-year improvement in the loss per share.
- Net loss improved materially
- Net loss was $43.1 million for the three months ended June 30, 2026, down from $52.7 million in the prior-year quarter; six-month net loss was $96.5 million versus $120.7 million in 2025.
- Cash runway extends into Q3 2027
- Cash, cash equivalents and marketable securities totaled $116.8 million as of June 30, 2026, which management expects to fund its operating plan into Q3 2027.
- ATM financing added $20.4 million
- The company received $20.4 million of net proceeds from ATM share sales during the six months ended June 30, 2026, providing additional liquidity but increasing reliance on equity financing.
- Pipeline refocused after MDD setback
- Management disclosed that development of navacaprant in MDD was discontinued in June 2026 after the Phase 3 KOASTAL-2 and KOASTAL-3 studies failed to achieve statistical significance on the primary or key secondary endpoints.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Finite cash runway and continuing losses
- The company reported accumulated losses of $1,280.7 million as of June 30, 2026 and stated that it expects significant losses for the foreseeable future. Its $116.8 million of cash, cash equivalents and marketable securities is expected to fund operations only into Q3 2027, creating a finite runway.
- Clinical pipeline execution risk
- Navacaprant development in MDD was discontinued in June 2026 after both Phase 3 KOASTAL-2 and KOASTAL-3 failed to achieve statistical significance, following the January 2025 KOASTAL-1 failure on its primary and key secondary endpoints.
- Debt conversion and equity dilution
- K2 HealthVentures had the right to convert up to $6.5 million of remaining term-loan principal into common stock as of June 30, 2026, while the company had also raised $20.4 million net through its ATM during the first six months of 2026, creating potential dilution and financing risk.
- Ongoing securities litigation
- The Securities Act putative class action filed on February 6, 2025 has progressed to a second amended complaint filed on May 5, 2026; defendants' reply brief on the motion to dismiss is due August 24, 2026, leaving ongoing litigation exposure.
- Variable-rate debt increases interest risk
- The term loan bears a variable rate equal to the greater of 10.45% or prime plus 2.95%, so higher rates could increase debt-service costs and reduce cash available for operations.
- Workforce reduction may disrupt execution
- Approximately 35% of the workforce was reduced in June 2026 following the navacaprant discontinuation, and the company had 63 full-time employees as of June 30, 2026; further organizational disruption could impair execution of remaining programs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.23
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management stated that $116.8 million of cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund the operating plan into Q3 2027.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Neumora Therapeutics reported a net loss of $53.5 million for Q1 2026, a notable improvement compared to the $68.0 million loss in Q1 2025. The company has maintained a strong cash position with $147.1 million on hand,…
- 10-K · March 30, 2026
- Neumora is a clinical-stage neuroscience-focused biotech advancing multiple CNS and metabolic programs with several near-term catalysts: joint KOASTAL-2 and -3 Phase 3 topline readouts expected in Q2 2026 and multiple…
- 10-Q · November 6, 2025
- Neumora reported a Q3 net loss of $(56,755)k (EPS $(0.35)), an improvement versus Q3 2024 net loss of $(72,547)k (EPS $(0.45)). Operating expenses declined as R&D fell to $40,520k from $60,630k and total operating…
- 10-K · March 3, 2025
- Neumora is a clinical-stage neuroscience company with a seven-program pipeline (two clinical, five preclinical) focused on novel mechanisms (KOR, V1aR, M4 PAMs). Its lead candidate navacaprant (NMRA-140) is in a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NMRA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever